Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $41.00 price target on the stock.
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum [Yahoo! Finance]
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum